BRISTOL MYERS SQUIBB

Bristol Myers Squibb's anemia drug Reblozyl failed to meet its primary endpoint of red blood cell transfusion independence in the Phase III INDEPENDENCE trial for myelofibrosis patients.

FDA advisers voted 5-3 against approving GSK's Blenrep in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma patients.

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

The FDA has identified significant ocular toxicity concerns with GSK's Blenrep (belantamab mafodotin) ahead of a July 17 advisory committee meeting to review the drug's reintroduction to the U.S. market.

A new American Cancer Society study reveals that immune checkpoint inhibitors, while improving survival across all insurance groups, have widened survival disparities between uninsured patients and those with private insurance for advanced melanoma, lung, and kidney cancers.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

The FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) programs and reduced post-treatment monitoring from four weeks to two weeks for Bristol Myers Squibb's CAR T-cell therapies Breyanzi and Abecma.

The FDA has approved label updates for Bristol Myers Squibb's CAR T cell therapies Breyanzi and Abecma, reducing patient monitoring requirements and removing Risk Evaluation and Mitigation Strategy (REMS) programs.

Incyte has appointed Bill Meury as its new CEO, effective immediately, replacing Hervé Hoppenot who led the cancer and blood disease drugmaker for 11 years.

Cigna filed a federal lawsuit against Bristol Myers Squibb, alleging the company used anti-competitive strategies to maintain a monopoly on Pomalyst, a multiple myeloma treatment that generated $2.7 billion in U.S. sales last year.